Physician profile
Nilima Desai
NPI 1801094834
$2,363.37
in general payments reported to CMS, 2019-2025
22 companies · $855 in 2025
The $855 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.38 · 2022: $25.18 · 2023: $433 · 2024: $1,023 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $615.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $271.91 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $270.27 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $237.32 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $153.77 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.50 | 2023-2024 | Xifaxan |
| Amgen INC. | $106.34 | 2019-2024 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $102.99 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.49 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $59.07 | 2024-2025 | |
| Astellas Pharma US INC | $53.92 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $50.71 | 2024-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $47.24 | 2024-2025 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $26.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.78 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $24.55 | 2025 | Pyrukynd |
| Mayne Pharma Commercial LLC | $23.62 | 2025 | |
| Dynavax Technologies Corporation | $22.56 | 2024 | Heplisav-B |
| Sumitomo Pharma America, INC. | $22.43 | 2024 | Gemtesa |
| Globus Medical, INC. | $21.17 | 2025 | Senza |
| Esperion Therapeutics, INC. | $20.12 | 2023 | Nexletol |
| Currax Pharmaceuticals LLC | $15.51 | 2023 | Nexletol, Contrave, Nexlizet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilima Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.